We have evaluated whether neutralising anti-streptokinase IgG antibodies are produced following streptokinase-streptodornase therapy of leg ulcer patients. Serum anti-streptokinase IgG concentrations in 10 leg ulcer patients were determined before, and 1 week, 2 weeks, and 3 weeks following the treatment. We observed only a negligible increase in neutralizing anti-streptokinase IgG concentrations during the observation period, which was probably of no therapeutical significance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/0001555574305306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of an immunoaffinity method for purification of streptokinase.
Avicenna J Med Biotechnol
July 2012
Department of Biology, Faculty of Science, Alzahra University, Tehran, Iran.
Background: Streptokinase is a potent activator of plasminogen to plasmin, the enzyme that can solubilize the fibrin network in blood clots. Streptokinase is currently used in clinical medicine as a thrombolytic agent. It is naturally secreted by β-hemolytic streptococci.
View Article and Find Full Text PDFHumoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction.
Eur Heart J
September 1999
Department of Medicine and Therapeutics, University of Leicester, Leicester, U.K.
Aims: Administration of streptokinase results in an immunological response which may lead to increased risk of anaphylactic reaction or reduced thrombolytic efficacy on repeat administration. For these reasons current recommendations suggest that streptokinase should not be given up to 1 year after first administration. We sought to define the profile of both the circulating antibody and T-cell response to streptokinase in patients who had received streptokinase up to 7.
View Article and Find Full Text PDFPlatelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets.
Thromb Res
May 1997
Unité de Pharmacologie Cellulaire, Institut Pasteur-INSERM U285, Paris, France.
Streptokinase (SK) is one of the plasminogen activators currently used in therapeutics. SK antibodies may appear in the blood after thrombolytic therapy with SK or after-hemolytic streptococci infection. Such antibodies may both activate platelets and neutralize the ability of SK to convert plasminogen into plasmin.
View Article and Find Full Text PDFSignal transduction in the platelet activation induced by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex.
Platelets
October 2012
Unité de Pharmacologic Cellulaire, Unité Associée Institut Pasteur-INSERM U285, 25, rue du Dr. Roux 75724, Paris, cedex 15, France.
Streptokinase (SK) is one of the plasminogen activators currently used in therapeutics. SK antibodies may appear in the blood after thrombolytic therapy with SK or after ss-hemolytic streptococci infection. Such antibodies may both activate platelets and neutralize the ability of SK to convert plasminogen into plasmin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!